A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid
A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.
Gespeichert in:
| Veröffentlicht in: | Organic letters 2022-12, Vol.24 (49), p.9049-9053 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9053 |
|---|---|
| container_issue | 49 |
| container_start_page | 9049 |
| container_title | Organic letters |
| container_volume | 24 |
| creator | Caravez, Juan C. Iyer, Karthik S. Kavthe, Rahul D. Kincaid, Joseph R. A. Lipshutz, Bruce H. |
| description | A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%. |
| doi_str_mv | 10.1021/acs.orglett.2c03683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9764352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753314488</sourcerecordid><originalsourceid>FETCH-LOGICAL-a258t-178a6811555529fec750b1015e2451584a2ecf814eb5ea9188de8e13a64bf7003</originalsourceid><addsrcrecordid>eNpVUctOwzAQtBCIQuELuPjIgbR-xIl7QaoqHhXlIQpcLSfdtEZpXGy3ojd-gV_kSzC0QmIvO9oZjXZ3EDqhpEMJo11d-o510xpC6LCS8EzyHXRABeNJTgTb_cMZaaFD718JoXHS20ctnqW5yCU9QGUf06-Pzwcb8HjdhBl447GtcER43H8cJwP7EnmGbxfO4mEzM4UJ1uE74-Y6OKhXxp39qm9gHfmpg4mBJmDT4Af9XtuVmRyhvUrXHo63vY2eLy-eBtfJ6P5qOOiPEs2EDAnNpc5kXDEW61VQ5oIUlFABLBVUyFQzKCtJUygE6B6VcgISKNdZWlQ5IbyNzje-i2Uxh0kZ13C6Vgtn5tqtldVG_WcaM1NTu1K9PEt5_FUbnW4NnH1bgg9qbnwJda0bsEuvWC44p2kqZZR2N9KYgnq1S9fEyxQl6ica9TPcRqO20fBve0aE3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2753314488</pqid></control><display><type>article</type><title>A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid</title><source>ACS Publications</source><creator>Caravez, Juan C. ; Iyer, Karthik S. ; Kavthe, Rahul D. ; Kincaid, Joseph R. A. ; Lipshutz, Bruce H.</creator><creatorcontrib>Caravez, Juan C. ; Iyer, Karthik S. ; Kavthe, Rahul D. ; Kincaid, Joseph R. A. ; Lipshutz, Bruce H.</creatorcontrib><description>A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.</description><identifier>ISSN: 1523-7060</identifier><identifier>EISSN: 1523-7052</identifier><identifier>DOI: 10.1021/acs.orglett.2c03683</identifier><identifier>PMID: 36475781</identifier><language>eng</language><publisher>American Chemical Society</publisher><subject>Letter</subject><ispartof>Organic letters, 2022-12, Vol.24 (49), p.9049-9053</ispartof><rights>2022 The Authors. Published by American Chemical Society</rights><rights>2022 The Authors. Published by American Chemical Society 2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-4566-2721 ; 0000-0003-4976-7432 ; 0000-0001-9116-7049 ; 0000-0002-5679-7536</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.orglett.2c03683$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.orglett.2c03683$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,776,780,881,27053,27901,27902,56713,56763</link.rule.ids></links><search><creatorcontrib>Caravez, Juan C.</creatorcontrib><creatorcontrib>Iyer, Karthik S.</creatorcontrib><creatorcontrib>Kavthe, Rahul D.</creatorcontrib><creatorcontrib>Kincaid, Joseph R. A.</creatorcontrib><creatorcontrib>Lipshutz, Bruce H.</creatorcontrib><title>A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid</title><title>Organic letters</title><addtitle>Org. Lett</addtitle><description>A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.</description><subject>Letter</subject><issn>1523-7060</issn><issn>1523-7052</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtBCIQuELuPjIgbR-xIl7QaoqHhXlIQpcLSfdtEZpXGy3ojd-gV_kSzC0QmIvO9oZjXZ3EDqhpEMJo11d-o510xpC6LCS8EzyHXRABeNJTgTb_cMZaaFD718JoXHS20ctnqW5yCU9QGUf06-Pzwcb8HjdhBl447GtcER43H8cJwP7EnmGbxfO4mEzM4UJ1uE74-Y6OKhXxp39qm9gHfmpg4mBJmDT4Af9XtuVmRyhvUrXHo63vY2eLy-eBtfJ6P5qOOiPEs2EDAnNpc5kXDEW61VQ5oIUlFABLBVUyFQzKCtJUygE6B6VcgISKNdZWlQ5IbyNzje-i2Uxh0kZ13C6Vgtn5tqtldVG_WcaM1NTu1K9PEt5_FUbnW4NnH1bgg9qbnwJda0bsEuvWC44p2kqZZR2N9KYgnq1S9fEyxQl6ica9TPcRqO20fBve0aE3w</recordid><startdate>20221216</startdate><enddate>20221216</enddate><creator>Caravez, Juan C.</creator><creator>Iyer, Karthik S.</creator><creator>Kavthe, Rahul D.</creator><creator>Kincaid, Joseph R. A.</creator><creator>Lipshutz, Bruce H.</creator><general>American Chemical Society</general><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4566-2721</orcidid><orcidid>https://orcid.org/0000-0003-4976-7432</orcidid><orcidid>https://orcid.org/0000-0001-9116-7049</orcidid><orcidid>https://orcid.org/0000-0002-5679-7536</orcidid></search><sort><creationdate>20221216</creationdate><title>A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid</title><author>Caravez, Juan C. ; Iyer, Karthik S. ; Kavthe, Rahul D. ; Kincaid, Joseph R. A. ; Lipshutz, Bruce H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a258t-178a6811555529fec750b1015e2451584a2ecf814eb5ea9188de8e13a64bf7003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caravez, Juan C.</creatorcontrib><creatorcontrib>Iyer, Karthik S.</creatorcontrib><creatorcontrib>Kavthe, Rahul D.</creatorcontrib><creatorcontrib>Kincaid, Joseph R. A.</creatorcontrib><creatorcontrib>Lipshutz, Bruce H.</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Organic letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caravez, Juan C.</au><au>Iyer, Karthik S.</au><au>Kavthe, Rahul D.</au><au>Kincaid, Joseph R. A.</au><au>Lipshutz, Bruce H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid</atitle><jtitle>Organic letters</jtitle><addtitle>Org. Lett</addtitle><date>2022-12-16</date><risdate>2022</risdate><volume>24</volume><issue>49</issue><spage>9049</spage><epage>9053</epage><pages>9049-9053</pages><issn>1523-7060</issn><eissn>1523-7052</eissn><abstract>A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.</abstract><pub>American Chemical Society</pub><pmid>36475781</pmid><doi>10.1021/acs.orglett.2c03683</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4566-2721</orcidid><orcidid>https://orcid.org/0000-0003-4976-7432</orcidid><orcidid>https://orcid.org/0000-0001-9116-7049</orcidid><orcidid>https://orcid.org/0000-0002-5679-7536</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-7060 |
| ispartof | Organic letters, 2022-12, Vol.24 (49), p.9049-9053 |
| issn | 1523-7060 1523-7052 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9764352 |
| source | ACS Publications |
| subjects | Letter |
| title | A 1‑Pot Synthesis of the SARS-CoV‑2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T23%3A11%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%201%E2%80%91Pot%20Synthesis%20of%20the%20SARS-CoV%E2%80%912%20Mpro%20Inhibitor%20Nirmatrelvir,%20the%20Key%20Ingredient%20in%20Paxlovid&rft.jtitle=Organic%20letters&rft.au=Caravez,%20Juan%20C.&rft.date=2022-12-16&rft.volume=24&rft.issue=49&rft.spage=9049&rft.epage=9053&rft.pages=9049-9053&rft.issn=1523-7060&rft.eissn=1523-7052&rft_id=info:doi/10.1021/acs.orglett.2c03683&rft_dat=%3Cproquest_pubme%3E2753314488%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2753314488&rft_id=info:pmid/36475781&rfr_iscdi=true |